FDA Requests Strengthened Warnings For Extended-Release Morphine Avinza
This article was originally published in The Pink Sheet Daily
Executive Summary
The labeling change request coincides with the withdrawal of Purdue's extended-release hydromorphone product Palladone due to the potential for serious alcohol-related adverse events. Ligand will intensify warnings about alcohol use with Avinza while further information on the risk is gathered.
You may also be interested in...
Health Canada Seeks Alcohol Interaction Data For Slow-Release Opioids
Manufacturers have six months to submit data on potential dose dumping due to interaction with alcohol.
Health Canada Seeks Alcohol Interaction Data For Slow-Release Opioids
Manufacturers have six months to submit data on potential dose dumping due to interaction with alcohol.
FDA Requests Expanded Alcohol Warnings For Extended-Release Morphine Kadian
Alpharma's Kadian joins the list of extended-release opioid analgesics for which FDA has requested expanded label warnings regarding alcohol following the withdrawal of Palladone. Alpharma is planning to conduct in vivo bioequivalence studies with Kadian to assess the clinical implication of the in vitro data.